PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer (Q27824857)

2

0 references

K Kawasaki

3

0 references

D Takabatake

4

0 references

H Takahashi

5

0 references

K Washio

6

0 references

K Tsukuda

7

0 references

Y Ogasawara

8

0 references

N Shimizu

British Journal of Cancer

9

0 references

language of work or name

English

0 references

publication date

30 January 2006

0 references

published in

0 references

volume

94

0 references

issue

2

0 references

page(s)

247-52

0 references

cites work

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361109

New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361109

The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361109

PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361109

Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361109

MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361109

Pten is essential for embryonic development and tumour suppression

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361109

Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361109

In vivo molecular pharmacology and antitumor activity of the targeted Akt inhibitor PX-316.

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361109

In vitro effects of trastuzumab and vinorelbine in trastuzumab-resistant breast cancer cells.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361109

Overexpression of ErbB2 in cancer and ErbB2-targeting strategies

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361109

Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361109

Analysis of the 10q23 chromosomal region and the PTEN gene in human sporadic breast carcinoma.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361109

PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361109

Ras signalling and apoptosis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361109

Immunohistochemical expression of the c-kit proto-oncogene product in human malignant and non-malignant breast tissues

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361109

A tiger behind many doors: multiple genetic pathways to malignant glioma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361109

PTEN/MMAC1 mutations in endometrial cancers.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361109

Unraveling resistance to trastuzumab (Herceptin): insulin-like growth factor-I receptor, a new suspect.

2 June 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6602926

Allelic loss of chromosome 10q23 is associated with tumor progression in breast carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6602926

Successful targeting of ErbB2 receptors-is PTEN the key?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6602926

Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6602926

The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6602926

Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6602926

Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6602926

Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6602926

Frequent inactivation of PTEN/MMAC1 in primary prostate cancer

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361109

Allelic loss of the PTEN region (10q23) in breast carcinomas of poor pathophenotype

27 November 2018

1 reference

12 December 2020

Overexpression of p53 and prognosis in breast cancer

1 reference

12 December 2020

Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies

1 reference

12 December 2020

Sporadic breast cancers exhibit loss of heterozygosity on chromosome segment 10q23 close to the Cowden disease locus

1 reference

12 December 2020

Breast cancer--loss of PTEN predicts resistance to treatment

1 reference

12 December 2020

Efficacy of trastuzumab

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJC.6602926

1 reference

Dimensions Publication ID

3558386

1012929330

0 references

3558386

1 reference

1 reference

1 reference